A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
Osnat BaireyAlisa TalianskyAmir GlikAlexandra AmielShlomit Yust-KatzRonit GurionMiri ZektserTzvika PorgesNadav SaridNetanel A HorowitzTzahala Tzuk ShinaEyal LebelAmos CohenKaryn Revital GeigerPia RaananiOfir WolachTali SiegalPublished in: Cancer (2023)
The study reached its primary end points and also showed that ibrutinib maintenance is tolerated reasonably well by the elderly. Therefore, this study supports the concept that ibrutinib maintenance should be further evaluated as an optional consolidation measure in the elderly.